-
Taltirelin Acetate: Applied Research Workflows
2026-09-20
Taltirelin acetate connects TRHR1 pharmacology with practical itch, neuroprotection, formulation, and sleep-related research workflows. This guide translates mouse evidence into executable assay design, dosing decisions, controls, and troubleshooting steps while separating established findings from exploratory applications.
-
Amphotericin B: Assay Design Beyond Membrane Lysis
2026-09-19
Amphotericin B is a polyene antifungal antibiotic whose membrane activity can be separated from immune and cytotoxic effects through layered assay design. This guide combines sterol biology, cytokine profiling, and lessons from a canine epithelial-cell study to improve fungal infection research reproducibility.
-
EPZ-6438: Precision EZH2 Inhibitor Workflows
2026-09-18
EPZ-6438 gives researchers a selective chemical handle for connecting EZH2 activity with H3K27me3 loss, transcriptional change, and cancer-cell phenotypes. This guide translates that mechanism into practical workflows for EZH2-mutant lymphoma, malignant rhabdoid tumor models, and combination studies in treatment-resistant melanoma.
-
FPS-ZM1 RAGE Inhibitor: Assay Workflow
2026-09-18
Use FPS-ZM1 to isolate RAGE-dependent effects in amyloid, hypothalamic, and neuroinflammation experiments. This practical workflow emphasizes solvent control, receptor confirmation, pathway-specific readouts, and careful interpretation of findings from berberine-based metabolic studies.
-
Bufuralol Hydrochloride in Translational Assays
2026-09-17
Bufuralol hydrochloride is a non-selective β-adrenergic receptor antagonist suited to mechanistic cardiovascular pharmacology research. This article presents a decision framework for pairing its established pharmacology with human iPSC-derived intestinal organoids without overstating what the model can prove.
-
Methoxy-X04 for Microglial Plaque Clearance
2026-09-17
Methoxy-X04 is a brain-permeable fluorescent amyloid beta probe for connecting plaque imaging with microglial clearance in Alzheimer’s disease models. This article interprets new exercise–muscle extracellular vesicle findings and translates them into more rigorous spatial, temporal, and mechanistic assay decisions.
-
Amyloid Beta-Peptide (1-40): Translational Strategy
2026-09-16
A mechanistic and strategic framework for using Amyloid Beta-Peptide (1-40) (human) to connect calcium-sensitive membrane biology, amyloid assembly, neurotoxicity models, and translationally relevant experimental design.
-
LY2886721: BACE1 Inhibition in AD Research
2026-09-16
LY2886721 is an oral BACE inhibitor with nanomolar activity in biochemical and cellular assays. Product data report amyloid beta reduction in HEK293Swe cells and PDAPP models, while peer-reviewed work defines a boundary between partial BACE1 inhibition and synaptic effects.
-
Dual HER2–VEGFR2 Targeting in TNBC Research
2026-09-15
The reference study examines whether lapatinib and Telatinib can jointly suppress invasive and angiogenic phenotypes in the HER2-negative MDA-MB-231 triple-negative breast cancer model. Its main contribution is a mechanism-oriented preclinical framework that connects drug response with invadopodia formation, proliferation, and 2D angiogenesis rather than relying on viability alone.
-
Amyloid Beta-Peptide (1-40): State-Specific Biology
2026-09-15
Amyloid Beta-Peptide (1-40) (human) is more than an aggregation model: its assembly state can determine whether an experiment measures receptor-proximal signaling, inflammatory regulation, or amyloid-associated injury. This article translates emerging APP-dependent microglial biology into practical assay decisions for Alzheimer’s disease research.
-
CD38 CAR Binder Structure and Affinity Tuning
2026-09-14
Cheng and colleagues define how the CD38-targeting binders RP02 and 028 recognize different antigen surfaces and produce distinct effects on CD38 enzymatic activity. Structure-guided attenuation of 028 reduced CAR-T fratricide while preserving cytotoxicity, establishing a mechanistic framework for balancing affinity, inhibition, and cellular selectivity.
-
Thiamet G: O-GlcNAcase Inhibitor Workflow
2026-09-14
Thiamet G turns O-GlcNAc turnover into a controllable experimental variable for tau, leukemia, metabolic, and bone-biology studies. This workflow links target engagement to pathway-specific readouts while showing how to avoid mistaking global O-GlcNAc elevation for proof of a single-substrate mechanism.
-
mRNA P1 Vaccine Protects Against M. pneumoniae
2026-09-13
The reference study develops an mRNA vaccine encoding the C-terminal region of the Mycoplasma pneumoniae P1 adhesin and evaluates antibody, T-cell, functional adhesion-inhibition, protection, and transcriptomic outcomes in mice. The results support mRNA-SP+P1 as a promising but still preclinical candidate, with significant partial protection against the vaccine-matched strain and partial cross-protection against a macrolide-resistant ST3 strain.
-
CHI3L1-IN-5 Workflow for Astrocyte Assays
2026-09-12
CHI3L1-IN-5 (Compound Z17) gives researchers a CNS-penetrant tool for connecting CHI3L1 signaling with inflammatory control, amyloid handling, and astrocyte recovery. This workflow emphasizes concentration-response design, orthogonal readouts, and troubleshooting strategies that distinguish pathway inhibition from nonspecific cellular effects.
-
Thiamet G for O-GlcNAcylation Research
2026-09-11
Thiamet G gives researchers a practical way to elevate protein O-GlcNAcylation while interrogating tau biology, Wnt-driven osteogenesis, and leukemia drug response. This guide translates its potency, solubility, and model-specific evidence into executable workflows with controls that distinguish pathway engagement from nonspecific toxicity.